Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?

Published:2016-07-22 Issue:12 Volume:63 Page:2104-2111
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Schmiegelow Kjeld¹²,Nersting Jacob¹,Nielsen Stine Nygaard¹,Heyman Mats³,Wesenberg Finn⁴,Kristinsson Jon⁵,Vettenranta Kim⁶,Schrøeder Henrik⁷,Weinshilboum Richard⁸,Jensen Katrine Lykke⁹,Grell Kathrine⁹,Rosthoej Susanne⁹,

Affiliation:

1. Department of Pediatrics and Adolescent Medicine; The University Hospital Rigshospitalet; Copenhagen Denmark

2. Faculty of Medicine; Institute of Clinical Medicine, University of Copenhagen; Denmark

3. Astrid Lindgrens Barnsjukhus; Stockholm Sweden

4. Department of Pediatric Oncology; The University Hospital Rikshospitalet; Oslo Norway

5. Department of Pediatric Oncology; The National Hospital; Reykjavik Iceland

6. Department of Pediatric Oncology; The University Hospital; Helsinki Finland

7. Department of Pediatric Oncology; Århus University Hospital; Denmark

8. Department of Pharmacology; Mayo Clinic; Rochester Minnesota

9. Section of Biostatistics, Department of Public Health; The University of Copenhagen; Copenhagen Denmark

Funder

Danish Childhood Cancer Foundation

Swedish Childhood Cancer Foundation

Danish Cancer Society

Lundbeck Foundation

Nordic Cancer Union

University Hospital Rigshospitalet

US National Institutes of Health;

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pbc.26139/fullpdf

Reference46 articles.

1. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction;Schmiegelow;J Pediatr Hematol Oncol,2014

2. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL;Tzoneva;Nat Med,2013

3. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia;Meyer;Nat Genet,2013

4. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia;Ma;Nat Commun,2015

5. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL;Li;Nat Med,2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

2. Bioequivalence study followed by model‐informed dose optimization of a powder for oral suspension of 6‐mercaptopurine;Pediatric Blood & Cancer;2023-12-18

3. Erythrocyte-incorporated 6-mercaptopurine metabolite levels are not affected by recent drug administration during maintenance therapy for childhood acute lymphoblastic leukemia;EJC Paediatric Oncology;2023-12

4. Impact of Mercaptopurine Metabolites on Disease Outcome in the AIEOP‐BFM ALL 2009 Protocol for Acute Lymphoblastic Leukemia;Clinical Pharmacology & Therapeutics;2023-08-24

5. Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer;Indian Journal of Pediatrics;2023-07-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3